Rimoli Maria Grazia

Biography

Prof. Maria Grazia Rimoli, born in Pozzuoli (NA) on 16/11/1963, graduated in Pharmacy in 1987 at the University of Naples "Federico II". In 1988 he was entrusted with a scientific collaboration with the Department of Pharmaceutical and Toxicology Chemistry of the Federico II University of Naples. Since November 1988 he has attended the fourth cycle of the PhD program in Pharmaceutical Sciences and in June 1992 he successfully passed the examination for the Ph.D. degree in Pharmaceutical Sciences. In March 1993, he was declared winner of 2 or competition for the award of a scholarship for postdoctoral two-year study. In 1995 he won the competition for a position as a researcher at the Faculty of Pharmacy of the University "Federico II" in Naples for the scientific-disciplinary sector CHIM / 08. In 1998 he was confirmed as a researcher and assigned to the full-time employment scheme. From 1999 to 2002 he was assigned an assignment for the teaching of "Drug Analysis II" for the University Diploma in Quality Control in the Industrial and Pharmaceutical Industry. In 2003 he won the competition for a position as associate professor at the Faculty of Pharmacy of the University "Federico II" in Naples for the scientific-disciplinary sector CHIM / 08. Since 2006 she is a Professor Associate Professor assigned to full-time employment. He has been a professor of "Analytical Chemistry and Analytical Analysis of I Medicines I" for 6 years in Pharmaceutical Chemistry and Pharmaceutical Technology and since 2009 has been teaching "Pharmacy and Toxicological Chemistry" for the three-year Degree Course in Quality Control. His research activity is carried out at the Department of Pharmaceutical and Toxicology Chemistry and is largely aimed at the synthesis of prophylaxis and new compounds for neuroprotective and analgesic activity. He is author of 28 journals in scientific journals, 1 book and inventor of 6 patents, including 2 internationals.

Research Interest

Synthesis of Profarmaci. Over the last decade, the strategy of the prodrug has been extensively studied and applied in the pharmaceutical industry. The substantial difference between a new synthetic drug and a drugstore is that the former is endowed with an intrinsic activity, while the latter requires in vivo enzymatic activationto exercise pharmacological activity. Given that the pharmacophore portion of the starting drug is not altered in the synthesis of the drug, the synthesis of prophylaxis is less difficult and the probability of being active is much higher than that of a new synthetic drug. The primary function of a drug store is to overcome the pharmaceutical and pharmacokinetic barriers that may appear in the clinical application of a drug such as toxicity, chemical instability, poor availability, lack of specificity and low tolerability by the drug. patient. The modern basis of the development of a prodrug is to combine, with the starting drug, chemical groups or specific vector molecules ( carriers ) that release the drug at the site of action (targeting ), to improve its cellular permeability, or to modify its pharmacokinetic profile to improve its bioavailability and decrease its toxicity. In our synthesis lab we have used sugars as the first choice carriers for the design and synthesis of new herbicides with different applications: Overcoming the Hematochemical Barrier (BEE) 1-3 ; Drug-targeting to tumor cells 4 ; Derivatization of non-steroidal anti-inflammatory drugs (NSAIDs) with the aim of reducing gastrointestinal toxicity after oral administration 5 . Synthesis of specific inhibitors for low T-type calcium channels. T type channels differ from high-threshold calcium channel channels such as L channels for their particular permeation properties due to their small single channel conductance when Ba 2+is used as a carrier ion, for their tendency to inactivate rapidly and for their ability to open in response to mild membrane depolarizations. Three different genes, coding for T channels, were cloned. According to the current nomenclature they are designated CaV3.1, CaV3.2 and CaV3.3. Type T channels take part in the response to neurotransmitters and neuropeptides such as dopamine, somatostatin, angiotensin II and endothelin. There are currently no specific blockers for such channels, approved for human use. The only exception to this assumption was Mibefradil which was approved for use in humans and has been used for some years as an antihypertensive drug. Unfortunately in 1998, this drug was removed from the market due to its pro-arithmetic activity and its propensity to cause dangerous drug-drug interactions. The search for new selective drugs for T-type can open new therapeutic perspectives for the treatment of epilepsy6 and in the tumor field, as their high hyper-expression was found in various types of human cancers such as breast cancer, gliomas, colorectal carcinomas, leukemia, retinoblastomas and prostate carcinomas.